| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PMVP | Common Stock | Sale | -$669K | -18.7K | -0.92% | $35.82 | 2.02M | Jul 21, 2021 | See footnote | F1, F2, F3 |
| transaction | PMVP | Common Stock | Sale | -$7.12K | -200 | -0.01% | $35.61 | 2.02M | Jul 22, 2021 | See footnote | F1, F3 |
| Id | Content |
|---|---|
| F1 | Shares were sold pursuant to a Rule 10b5-1 trading plan. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.60 to 36.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F3 | The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. |